Gyre Therapeutics Announces Results of 2026 Annual Meeting and Approval of Series B Conversion

Gyre Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected David M. Epstein, Ph.D., and Dan Weng, M.D., as Class II directors to serve until the 2029 Annual Meeting. Additionally, stockholders approved three other key proposals: a non-binding advisory vote on executive compensation, the ratification of Grant Thornton Zhitong Certified Public Accountants LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and the issuance of common stock upon the conversion of the company’s Series B Convertible Preferred Stock in accordance with Nasdaq Listing Rule 5635(a). As of the record date, April 16, 2026, there were 96,994,001 shares of common stock entitled to vote. All director nominees were elected, and all proposals passed with significant majorities.